Missed Out on Vaccine Stocks? My Best Biotech Stock to Buy and Hold
Coronavirus vaccine stocks were among the best performers on the market over the past couple of years. Novavax soared by 2,700% in 2020 on optimism about its COVID-19 program. Moderna (NASDAQ: MRNA) climbed by 1,200% and BioNTech gained more than 600% from the start of 2020 through the end of last year. Even pharma giant Pfizer rose 59% during that period.
If you missed out on those big gains, you should recognize that vaccine stocks probably won't repeat those stellar performances. But there are still plenty of investment opportunities out there in the world of healthcare -- especially if you plan to buy and hold shares for the long term. One of those strong opportunities just so happens to be a coronavirus vaccine stock -- today. But its next growth drivers may come from other indications.
The company I'm talking about is none other than Moderna. We all think of its popular COVID-19 vaccine when we think of this innovative biotech player. That's natural -- the vaccine is its only commercialized product right now. But there's a whole lot more to Moderna.
Source Fool.com
